46911-83-5

Basic information

• Product Name: Benzyl (2,5-dioxo-1,3-oxazolidin-4-yl)acetate
• Synonyms: Benzyl (2,5-dioxo-1,3-oxazolidin-4-yl)acetate
• CAS NO: 46911-83-5
• Molecular Formula: C12H11NO5
• Molecular Weight: 249.21944
• Mol File: 46911-83-5.mol
• Article Data: 41

Chemical Properties

• Appearance: /
• Density: 1.332g/cm³
• Refractive Index: 1.546
• CAS DataBase Reference: Benzyl (2,5-dioxo-1,3-oxazolidin-4-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl (2,5-dioxo-1,3-oxazolidin-4-yl)acetate(46911-83-5)
• EPA Substance Registry System: Benzyl (2,5-dioxo-1,3-oxazolidin-4-yl)acetate(46911-83-5)

Safety Data

• Hazardous Substances Data: 46911-83-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 16, p. 1513, 1951 DOI: 10.1021/jo50004a004

InChI:InChI=1/C12H11NO5/c14-10(6-9-11(15)18-12(16)13-9)17-7-8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,16)/t9-/m1/s1

Upstream product

• 3479-47-8 Z-Asp(OBzl)-OH 
• 75-44-5 phosgene 
• 2177-63-1 (S)-2-amino-4-(benzyloxy)-4-oxobutanoic acid 
• 79-37-8 oxalyl dichloride 
• 130529-78-1 C₂₂H₃₅NO₆Si 
• 503-38-8 trichloromethyl chloroformate 
• 100-51-6 benzyl alcohol 
• 5241-60-1 di(phenylmethyl) (2S)-2-[(phenylmethoxy)carbonylamino]-butane-1,4-dioate 
• 1152-61-0 N-Cbz-L-Asp 
• 104-15-4 toluene-4-sulfonic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 29880-21-5 β-benzyl N-benzyloxycarbonyl-DL-aspartate 
• 5241-60-1 N-benzyloxycarbonyl-DL-aspartic acid dibenzyl ester 

Relevant articles and documents

Synthesis of α-Amino Acid N-Carboxyanhydrides

A simple phosgene- and halogen-free method for synthesizing α-amino acid N-carboxyanhydrides (NCAs) is described. The reaction between Boc-protected α-amino acids and T3P reagent gave the corresponding NCA derivatives in good yield and purity with no detectable epimerization. The process is safe, is easy-to-operate, and does not require any specific installation. It generates nontoxic, easy to remove byproducts. It can apply to the preparation of NCAs for the on-demand on-site production of either little or large quantities.

Block copolymer [(l-GluA-5-BE)-: B -(l-AspA-4-BE)]-based nanoflower capsules with thermosensitive morphology and pH-responsive drug release for cancer therapy

Herein, the synthesis of an amino-acid-based di-block copolymer (di-BCP) in-between an l-glutamic acid-5-benzyl ester and l-aspartic acid-4-benzyl ester [(l-GluA-5-BE)-b-(l-AspA-4-BE)] has been reported. However, the synthesis of di-BCP of [(l-GluA-5-BE)-b-(l-AspA-4-BE)] was carried out through the facile modified ring-opening polymerization (ROP) without using any surfactants and harmful chemicals. Interestingly, the synthesized [(l-GluA-5-BE)-b-(l-AspA-4-BE)] has been used to design nanoflower capsules (NFCs) with surface-functionalized nanoflakes and petals. Notably, the simple solvent propanol has been used as a dispersing medium for the di-BCP-based powder to observe morphology of NFCs. Moreover, these amino-acid-based NFCs are biocompatible, biodegradable, and bio-safe for mankind usage. Consequently, di-BCP-based NFCs show changes in morphology with different temperature conditions, i.e., at ～10 °C, ～25 °C (RT), and ～37 °C (body temperature). Furthermore, the average thickness of the surface-functionalized nanopetals has been calculated as ～324 nm (in diameter). Similarly, the average distance between petals is calculated as 3.6 μm and the pore depth is ～21 nm. Additionally, the porosity throughout the surface of capsules in-between nanopetals is an advantageous characteristic feature to improve the drug/paclitaxel (PTX) loading capacity. It is a unique and novel approach to design NFCs, which are a potential payload for nanomedicine and cancer therapy. Furthermore, NFCs were used to evaluate the loading efficacy of drugs and showed ～78% (wt/wt%) of the PTX loading. Moreover, NFCs showed ～74% drug release at physiological body temperature. Thus, NFCs showed remarkable release at acidic pH medium. However, PTX released from NFCs showed greater cell inhibition (i.e., ～79%) with an increase of the PTX concentration after 24 h incubation over HeLa (human epithelial cervical cancer) cells. Besides, PTX released from NFC showed significant (～34%) cell killing capacity. Such promising NFCs are recommended for breast, liver, and lung cancer therapeutics.

Preparation method of drug-loaded nano-micelle capable of releasing anti-cancer drug in tumor matrix as well as product and application of drug-loaded nano-micelle

The invention relates to a preparation method of a drug-loaded nano-micelle capable of releasing an anti-cancer drug in a tumor matrix as well as a product and an application of the drug-loaded nano-micelle, which belongs to the technical field of drug carriers. The preparation method comprises the following steps: the beta-benzyl aspartate is prepared, benzyloxycarbonyl aspartic anhydride is prepared, a polyaspartic acid benzyl ester polymer is prepared, a carboxylation-polyaspartic acid benzyl ester polymer is prepared, a carboxyl-polyaspartic acid dimethylethylenediamine polymer is prepared, a polyaspartic acid dimethylethylenediamine-polyaspartic acid benzyl ester polymer is prepared, a poly(aspartic acid-dimethylethylenediamine)-poly (aspartic acid-mercaptoethylamine) polymer is prepared, and drug-loaded nano-micelle for releasing an anti-cancer drug in a tumor matrix is prepared. The drug-loaded nano-micelle prepared by the preparation method has double sensitivities of pH sensitivity and reduction sensitivity, can accurately release drugs, and effectively improves the tumor treatment effect.